After receiving immunotherapy based on personalized neoantigen loading, the metastasis in the whole body completely subsided. Individualized immunotherapy based on neoantigens may become a new hope for conquering cancer!
After decades of research, researchers have found the cancer cells' fatal weakness -specific neoantigens. This is an abnormal protein produced by cancer cells through mutations. It only exists in cancer cells, but not in normal cells. Therefore, it is a non-autologous antigen that can specifically activate the human immune system and is an ideal target for individualized immunotherapy.
Based on this, researchers have developed individualized immunotherapy based on specific neoantigens present in each patient's tumor! In 2022, the global cancer " neoantigen vaccine " has been developing everywhere, and has obtained exciting clinical data. It has set off a new wave of tumor immunotherapy , which is expected to become a new anti-cancer tool and help countless patients overcome cancer!
1. Head and neck cancer: the disease control rate of neoantigen vaccine mRNA-4157 is as high as 90%!
mRNA-4157 is an individualized neoantigen tumor vaccine tailored for every tumor patient. It was developed by the famous biological company Moderna.
latest clinical trial data codenamed KEYNOTE-603 shows that mRNA-4157 combined with Keytruda can reduce a variety of advanced solid tumor lesions, especially for head and neck tumors, with excellent data.
In 10 HPV-negative patients with head and neck squamous cell carcinoma, the total response rate was 50% : 2 complete responses and 3 partial responses. At the same time, the four patients had stable disease, and the disease control rate (DCR) reached 90% . exceeded many targeted and immunotherapy drugs that have been launched, which is very exciting.
Molly Cassidy is one of the lucky ones who have completely relieved. She was diagnosed with head and neck cancer in 2019, and her condition recurred after surgery, and chemoradiation and chemotherapy. At the time of desperate silence, Molly chose to undergo clinical experiments on this vaccine. The doctor told her that this treatment is to use the patient's own cancer cells to develop a vaccine to stimulate the patient's own immune system to recognize and eliminate cancer.
After receiving treatment with a personalized vaccine tailored for her, Molly's immune system responded well. Within a year after she started the treatment, she obtained to completely relieve , which means that all her tumors disappeared and there was no sign of cancer in her body! Original link: The advanced tumor is completely relieved! The new cancer vaccine allows her to create a miracle of rebirth!
researchers said: " Our ultimate goal is to make every cancer patient like Molly. We are expanding research on how to better apply this treatment to more patients to achieve more successful results. "
2. non-small cell lung cancer : PD-1 is there any rescue after resistance to drugs? The neoantigen vaccine Tedopi is expected to "spend life"
Tedopi (OSE2101) is a neoantigen vaccine specifically targeting non-small cell lung cancer. Its innovative design is different from previous attempts. Tedopi targets five tumor-related antigens frequently expressed in lung cancer cells, and then selects and optimizes 10 new epitopes from these five tumor-related antigens, which can better stimulate T lymphocytes to recognize and attack cancer cells.
Preliminary data show that overall survival (OS) can be improved in patients with HLA-A2+ NSCLC who develop secondary resistance after treatment with sequential chemotherapy-immune checkpoint inhibitor (PD-1) compared with standard treatment (SoC docetaxel or pemetrexed).
The latest results released at this year's ASCO conference showed that : 118 patients with advanced non-small cell lung cancer who are resistant to PD-1, 95 are finally available for evaluation. The median overall survival was 11.1 months in the Tedopi vaccine group, compared with 7.5 months in the chemotherapy group.Therefore, in patients with advanced HLA-A2+ NSCLC after chemotherapy and immunotherapy failure, vaccines can significantly improve survival. Original link: Important! The data on the Phase III trial of the new lung cancer vaccine Tedopi is released, which can actually crack PD-1 resistance!
3. gastric cancer : treatment for 1 year of systemic tumor regresses! The Guoyan neo-MoDC made a major breakthrough in the Guoyan neo-antigen vaccine
In June 2022, a research on the Guoyan neo-antigen vaccine published in the sub-blog of the international blockbuster journal Nature caused a huge sensation. After receiving the Neo-MoDC (personalized neoantigen-loaded dendritic cell) vaccine and PD-1 for the first time, the lesion completely disappeared and lasted for up to 25 months. This is the first known study to achieve complete and lasting tumor regression through neoantigen-based DC vaccine and PD-1 treatment in gastric cancer, which is of milestone significance!
Neo-MoDC is a personalized dendritic cell vaccine that carries neoantigen-carried -derived dendritic cell vaccine. The new cancer vaccine can fully mobilize the immune system: dendritic cells (DCs) recognize cancer antigen-present antigen-activate T cells-promote T cell enrichment-mobilize T cells to clear cancer cells, and finally complete a series of precision and powerful attacks on cancer cells throughout the body.
We look forward to the release of more excellent clinical data for this vaccine and be launched as soon as possible to benefit patients.
4. liver cancer : Effectively prevent recurrence! Guoyan's new antigen vaccine was born
In June 2022, a cancer vaccine developed by Chinese researchers that can effectively prevent the recurrence of liver cancer was released in the internationally renowned journal "Cancer Immunology Research", causing a sensation. It is worth mentioning that this is the world's first phase II clinical trial of dendritic cell (DC) vaccine based on tumor neogenic antigen and combination of adoptive T cell therapy to prevent liver cancer recurrence. The latest results of
show that among the 10 patients with hepatocellular carcinoma who underwent radical resection or radiofrequency ablation, 71.4% of patients with did not recur within 2 years after curative treatment.
researchers believe that neoantigens-based combined immunotherapy is feasible, safe, and has the potential to reduce recurrence of liver cancer after curative treatment.
Want to seek new technologies to prevent relapse and other domestic and foreign treatment assistance. If economic conditions allow, patients can first submit their medical records to the Department of Medicine of the Global Cancer Doctors Network (400-666-7998) for preliminary evaluation.
We also look forward to the early blooming and bear fruit of the Chinese cancer vaccine, bringing new hope to Chinese cancer patients in desperate situations!
5: Colorectal cancer: The neoantigen vaccine GRT901 is expected to prolong survival and prevent recurrence!
The treatment options for most patients with metastatic colorectal cancer (mCRC) are limited primarily to cytotoxic chemotherapy, with little progress over the past decade. Encouragingly, patients with dMMR/MSI-H benefit from checkpoint inhibitors (CPI), while patients with pMMR/MSS lack immunotherapy with clinical benefit.
Data from a phase 1/2 study evaluated the combination of neoantigens vaccines with immune checkpoint inhibitors in patients with previously treated metastatic colorectal cancer. GRT-C901/GRT-R902 is a personalized enhanced cancer vaccine containing mRNA of a patient's tumor-specific neoantigens, which may lead to an increased antitumor immune response against neoantigens-expressing tumor cells. This vaccine is expected to reduce circulating tumor cells in patients with MSS-type colorectal cancer and prolong overall survival.
It is necessary to remind everyone that most of the cancer vaccines mentioned above are currently in the early stage of clinical trials. Dendritic cell vaccines in some countries have officially entered clinical application. Early tumor patients can consider using vaccines combined with chemoradiation and therapy after surgery to kill residual cancer cells, produce immune memory, and prevent cancer recurrence and metastasis. Everyone consults the Department of Medicine of Global Oncology Doctors Network.
new antigen vaccine is being unlocked at an accelerated pace, and it is expected to become a powerful tool to overcome cancer!
Fifty years ago, humans ended the raging smallpox by passing vaccines, measles .
But unlike this preventive vaccine, researchers around the world are actively developing therapeutic cancer vaccines that can awaken our immune system and kill cancer cells, while producing an immune memory response, so that the immune system can continue to protect our therapeutic cancer vaccines for the next decade or even life. Once the injection takes effect, whenever cancer cells appear in the body, the immune system can automatically attack, allowing them to kill them before they form a tumor, protecting us from cancer!
believes that this idea will become a reality!
Reference:
https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-clinical-updates-personalized-cancer-vaccine
https://endpts.com/a-cancer-vaccine-that-mig http-work-moderna-posts-promising-early-snapshot-for-merck-partnered-program-and-raids-bristol-myers-for-a-new-cancer-rd-chief/
https://uahs.arizona.edu/tomorrow/immunotherapy-cancer-vaccine-trial-offers-patients-new-hope
